CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug
The Australian drugmaker CSL will pay $355 million for Alentis Therapeutics’ anti-fibrosis drug, plus as much as $1.2 billion in future payments. Under the deal announced Sunday evening, CSL will co-develop ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.